

**ONTARIO
SUPERIOR COURT OF JUSTICE**

THE HONOURABLE) FRIDAY, THE 4TH DAY
)
JUSTICE PERELL) OF NOVEMBER, 2022
)

B E T W E E N :

TAMMY CURRIE

Plaintiff

- and -

DAVOL, INC., C.R. BARD, INC., BARD CANADA INC., GENZYME CORPORATION,
and SANOFI S.A.

Defendants

Proceeding under the *Class Proceedings Act, 1992*

ORDER


THIS MOTION, made by the Plaintiff, for an Order approving the discontinuance of the within action against Sanofi S.A, without costs, and without prejudice, was heard in writing on November 4, 2022, at the Superior Court of Justice, 361 University Avenue, Toronto, Ontario, M5G 1T3.

ON READING the materials filed, including the consent of the Defendants, Genzyme Corporation and Sanofi S.A., and

ON NOTING that the Defendants, Davol, Inc., C.R. Bard, Inc., and Bard Canada Inc., take no position on the motion:

1. **THIS COURT ORDERS** that the within action be and is hereby discontinued as to the Defendant Sanofi S.A. on a without costs and without prejudice basis.

2. **THIS COURT DECLARES** that a Notice of Partial Discontinuance, substantially in the form attached as Schedule "A", is approved pursuant to s. 19 of the *Class Proceedings Act, 1992*, S.O. 1992, c. 6.
3. **THIS COURT ORDERS** that the Notice of Partial Discontinuance shall be posted on the website of each putative Class Counsel firm.
4. **THIS COURT ORDERS** that, in the event that the Plaintiff subsequently moves for leave to add Sanofi S.A. as a defendant in this action and such relief is granted, service of such claim can be affected by serving a copy of the claim on Sanofi S.A.'s counsel of record in this action. Any such motion must be brought on notice to Sanofi S.A., served on its counsel of record in this action.
5. **THIS COURT ORDERS** that there be no costs of this motion.



The Honourable Justice Perell

SCHEDULE “A”

NOTICE OF PARTIAL DISCONTINUANCE

On June 15, 2017, a proposed class action was commenced in Ontario against Davol Inc., C.R. Bard Inc., Bard Canada Inc., Genzyme Corporation, and Sanofi S.A., with respect to Sepramesh products, a form of surgical mesh product that was used in hernia repairs.

On November 4, 2022, the Ontario Superior Court of Justice approved a discontinuance of the action against Sanofi S.A., on a without costs and without prejudice basis. The discontinuance relates only to Sanofi S.A. The action will continue against the other defendants.

For more information regarding this proposed class action, please contact Plaintiff’s counsel: [Insert information for Siskinds LLP (herniamesh@siskinds.com or [1-800-461-6166](tel:1-800-461-6166)) or McKenzie Lake Lawyers LLP (noble@mckenzielake.com or [1-844-672-5666](tel:1-844-672-5666)), as the case may be, dependant on the Class Counsel website where the notice is posted.]

TAMMY CURRIE and BARD CANADA INC. et al
Plaintiff Defendants

Court File No.: CV-17-577209-00CP

ONTARIO
SUPERIOR COURT OF JUSTICE

Proceeding commenced at Toronto

Proceeding under the *Class Proceedings Act, 1992*

ORDER
(DISCONTINUANCE)

SISKINDS LLP

275 Dundas Street, Unit 1
London, ON N6B 3L1

Charles M. Wright (LSO: 36599Q)
charles.wright@siskinds.com
Jill S. McCartney (LSO: 50632S)
jill.mccartney@siskinds.com
Tel: (519) 672-2121
Fax: (519) 672-6065

MCKENZIE LAKE LAWYERS LLP

140 Fullarton Street; Suite 1800
London, ON N6A 5P2

Michael J. Peerless (LSO: 34127P)
mike.peerless@mckenzielake.com
Matthew D. Baer (LSO: 48227K)
matt.baer@mckenzielake.com
Tel: (519) 672-5666
Fax: (519) 672-2674

Lawyers for the Plaintiff